Evaluation of VMX-C001 for Coagulation Restoration in Patients on DOACs Experiencing Bleeding or Requiring Anticoagulation Reversal Prior to Urgent Surgery

The primary objective of this study is to evaluate the **safety**, **tolerability**, uptake, and efficacy of VMX-C001 in healthy volunteers. This is clinically relevant as it aims to restore coagulation in patients taking direct oral anticoagulants (DOACs) who are experiencing bleeding or require reversal of anticoagulation prior to urgent surgery. The ability to effectively manage coagulation in such scenarios is critical for patient safety and optimal surgical outcomes.

The clinical trial involves a study population comprising both **male** and **female** participants, with an age range that includes adults and the elderly. The trial is focused on patients who require the restoration of coagulation due to bleeding or the need for reversal of anticoagulation prior to urgent surgery, specifically those taking direct oral anticoagulants (DOACs). The general health status of participants is not specified, and there are no indications of the inclusion of a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet or physical activity. The selection criteria for the trial population have not been detailed, and no principal inclusion criteria have been disclosed.

The clinical trial is designed to evaluate the **safety**, tolerability, uptake, and efficacy of VMX-C001 in healthy volunteers. This study is a Phase 3 trial, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the treatment to be used safely. The trial is expected to run from November 6, 2023, to November 6, 2024. The primary medical condition being addressed is the restoration of coagulation in patients taking direct oral anticoagulants (DOACs) who are experiencing bleeding or require reversal of anticoagulation prior to urgent surgery.

The trial will follow a **randomized**, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group receiving VMX-C001 or a control group. Neither the participants nor the researchers will know which group the participants are in, which helps to prevent bias in the results.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants will be assessed for eligibility based on predefined criteria. This visit will include a comprehensive review of the participant's medical history and a series of baseline assessments. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits at specified intervals to monitor their health status, adherence to the study protocol, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the trial.

The end-of-study visit will occur at the conclusion of the trial period, where final assessments will be conducted to evaluate the overall outcomes of the treatment. The expected length of participant involvement is approximately one year, aligning with the overall trial duration. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with the study protocol, or choose to withdraw their consent.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on November 6, 2023, with an estimated completion date of November 6, 2024. The efficacy assessment will be conducted in accordance with the trial's protocol, which is aligned with the standards for Phase 3 clinical trials. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and schedule for measuring, collecting, and analyzing these parameters, are not detailed in the provided data. The trial will adhere to rigorous scientific and ethical standards to ensure the validity and reliability of the efficacy outcomes.